Search
for
Sort by
Research 31–60 of 532
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- A novel therapeutic paradigm for patients with extensive alopecia areata
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction
- New drugs under investigation for the treatment of alopecias
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- <i>Lagerstroemia indica</i> extract regulates human hair dermal papilla cell growth and degeneration via modulation of β‐catenin, Stat6, and TGF‐β signaling pathway
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Janus Kinase inhibitors in dermatology: a review
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- The role of janus kinases in the treatment of autoimmune skin diseases
- Pharmacological Treatment of Alopecia